Stories about Krankheit
- more
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
more- 2
Free Access to Cancer Research Services - canSERV 1st Call for Proposals
more Free Access to Cancer Research Services - canSERV 1st Call for Proposals
One documentmoreInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
One documentmoreType 1 Diabetes Awareness Campaign - K1DS ARE HEROES - started
more
Breakthrough - EUR 50 million investment for start-up BrainRepair UG / Pivotal trial on stem cell treatment for brain damage in newborns fully funded
moreTechnische Universität München
New X-ray technology can improve Covid-19 diagnosis
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Images: https://mediatum.ub.tum.de/1692790 NEWS RELEASE New X-ray technology can improve Covid-19 diagnosis Patient study demonstrates benefits of dark-field X-ray technology A research team at the Technical University of Munich (TUM) has, for the first time, produced dark-field X-ray images of ...
moreTechnische Universität München
Why are overweight people more susceptible to illness?
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22778 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/news-and-events/all-news/press-releases/details/warum-bekommen-uebergewichtige-menschen-haeufiger-erkrankungen Picture: https://mediatum.ub.tum.de/1612044 NEWS RELEASE Why are overweight people more susceptible to illness? Size of fat cells can cause ...
moreFlu tests from R-Biopharm also detect new virus variants
moreStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research
moreTechnische Universität München
Alzheimer's disease and type 2 diabetes: Synthetic peptides may suppress formation of harmful amyloid aggregates
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22779 - email: presse@tum.de - web: www.tum.de Image download: https://mediatum.ub.tum.de/652209?show_id=1691364 NEWS RELEASE Alzheimer's disease and type 2 diabetes: Synthetic peptides may suppress formation of harmful amyloid ...
more
Klinik für Prostata-Therapie Heidelberg
Focal therapy for prostate cancer: Reliable diagnosis leads to gentle treatment
moreType 1 diabetes: New findings on the development of the autoimmune disease in children
moreSwitching tracks: Changing the trafficking of the glucagon receptor in the liver regulates its metabolic signaling
morebenfovir AG has reached another milestone by completing the first part of the Phase 1 trial testing transketolase inhibitor / benfo-oxythiamine (B-OT)
Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...
moreLandscape of molecular contacts: How the coronavirus SARS-CoV-2 communicates with human cells
moreTechnische Universität München
Improved monitoring of silicone implants
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/aktuelles/alle-meldungen/pressemitteilungen/details/verbessertes-monitoring-von-silikonimplantaten Pictures: https://mediatum.ub.tum.de/1687409 NEWS RELEASE Improved monitoring of silicone implants New algorithm for clinical MRI scanners makes breast ...
more
European Society for Medical Oncology (ESMO)
ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...
moreEfficient AI technology for MRI data analysis
more- 2
Vitamin K prevents cell death: a new function for a long-known molecule
more Technische Universität München
Viruses help combat antibiotic-resistant bacteria - Cell-free production of bacteriophages
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37533 High resolution images: https://mediatum.ub.tum.de/1678288 NEWS RELEASE Viruses help combat ...
moreR-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories
moreTechnische Universität München
New center for digital medicine and health
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37491 Images: https://mediatum.ub.tum.de/1663381 NEWS RELEASE Interdisciplinary research for the digital medicine of the future Federal and state governments approve funding for digital medicine and health center ...
more
UK MEDTECH COMPANY TO HELP PROTECT US HEALTHCARE WORKERS AND US CITIZENS FROM 1 MILLON NEEDLESTICK INJURIES EACH YEAR
Liverpool England and Philadelphia USA (ots) - --News Direct-- SAFETY INITIATIVE AND COMPLIANCE WILL SAVE AMERICAN HEALTHCARE INDUSTRY $1 BILLION British smart MedTech company NeedleSmart, which is pioneering disruptive technologies in the global healthcare sector, is expanding into the US healthcare market to ...
morebenfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT/ B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS
Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...
moreEuropean Inventor Award 2022: Meet the inventors that are shaping our world at virtual event
Munich (ots) - - The winners of the European Patent Office’s annual innovation prize will be revealed at a ceremony on 21 June 2022 at 12:00 CEST held in an all-new format - Discover the stories of 14 exceptional inventor teams and 4 young innovators from 14 countries - The public is now invited to vote for their favourite inventor to win the Popular Prize at ...
moreALDERHEY@NYWHERE(TM)
Liverpool, England (ots) - CREATING A HOSPITAL OF THE FUTURE: "A HOSPITAL WITHOUT WALLS" ALDER HEY LAUNCHES GROUND-BREAKING HYBRID DIGITAL HEALTH PLATFORM IN COLLABORATION WITH MICROSOFT AND MINDWAVE "TODAY'S CHILD, TOMORROW'S HEALTHIER ADULT" Alder Hey Children's NHS Foundation Trust, one of the world's leading paediatric healthcare institutions, has today launched a ground-breaking digital platform that is set to revolutionise the way in which patient care is delivered to ...
moreR-Biopharm announces test to detect monkeypox virus
moreTechnische Universität München
Same symptom – different cause? Algorithms help to distinguish diseases at the molecular level
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37411 High resolution images: https://mediatum.ub.tum.de/1659820 NEWS RELEASE Same symptom – different cause? Algorithms help to distinguish diseases at the ...
more